@article{66b041ff4c094623b3c399dcad091d4c,
title = "Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion",
abstract = "Su et al. develop two potent small-molecule inhibitors against an RNA N6-methyladenosine demethylase called FTO. FTO inhibition shows anti-tumor effects in several types of cancers in mouse models by restricting self-renewal of cancer stem cells and suppressing immune evasion.",
keywords = "FTO, LILRB4, LSC/LIC self-renewal, N-methyladenosine (mA) modification, immune checkpoint genes, immune evasion, inhibitors, leukemia, solid tumors, therapeutics",
author = "Rui Su and Lei Dong and Yangchan Li and Min Gao and Li Han and Mark Wunderlich and Xiaolan Deng and Hongzhi Li and Yue Huang and Lei Gao and Chenying Li and Zhicong Zhao and Sean Robinson and Brandon Tan and Ying Qing and Xi Qin and Emily Prince and Jun Xie and Hanjun Qin and Wei Li and Chao Shen and Jie Sun and Prakash Kulkarni and Hengyou Weng and Huilin Huang and Zhenhua Chen and Bin Zhang and Xiwei Wu and Olsen, {Mark J.} and Markus M{\"u}schen and Guido Marcucci and Ravi Salgia and Ling Li and Fathi, {Amir T.} and Zejuan Li and Mulloy, {James C.} and Minjie Wei and David Horne and Jianjun Chen",
note = "Funding Information: We thank Dr. Cai-Guang Yang from Shanghai Institute of Materia Medica, Chinese Academy of Sciences for providing FB23-2 and for his guidance in the NMR analysis. We thank Dr. Mi Deng and Dr. Cheng Cheng Zhang from University of Texas Medical Center for providing the pLVX-ZsGreen and ZsGreen-hLILRB4. We acknowledge the support of the Hematopoietic Tissue Biorepository core at City of Hope Comprehensive Cancer Center, which is supported by the National Cancer Institute of the US National Institutes of Health (NIH) under award number P30CA33572 . This work was supported in part by the NIH grants R01 CA243386 (J.C.), R01 CA214965 (J.C.), R01 CA236399 (J.C.), R01 CA211614 (J.C.), R01 DK124116 (J.C.), The Margaret Early Medical Research Trust (R. Su), American Cancer Society Research Scholar grant (Z.L.), NIH R50CA211404 (M.W.), R35CA197628 (M.M.), U10CA180827 (M.M.), R01CA137060 (M.M.), R01CA157644 (M.M.), R01CA172558 (M.M.), and R01CA213138 (M.M.). J.C. is a Leukemia & Lymphoma Society Scholar. M.M. is a Howard Hughes Medical Institute Faculty Scholar. Funding Information: We thank Dr. Cai-Guang Yang from Shanghai Institute of Materia Medica, Chinese Academy of Sciences for providing FB23-2 and for his guidance in the NMR analysis. We thank Dr. Mi Deng and Dr. Cheng Cheng Zhang from University of Texas Medical Center for providing the pLVX-ZsGreen and ZsGreen-hLILRB4. We acknowledge the support of the Hematopoietic Tissue Biorepository core at City of Hope Comprehensive Cancer Center, which is supported by the National Cancer Institute of the US National Institutes of Health (NIH) under award number P30CA33572. This work was supported in part by the NIH grants R01 CA243386 (J.C.), R01 CA214965 (J.C.), R01 CA236399 (J.C.), R01 CA211614 (J.C.), R01 DK124116 (J.C.), The Margaret Early Medical Research Trust (R. Su), American Cancer Society Research Scholar grant (Z.L.), NIH R50CA211404 (M.W.), R35CA197628 (M.M.), U10CA180827 (M.M.), R01CA137060 (M.M.), R01CA157644 (M.M.), R01CA172558 (M.M.), and R01CA213138 (M.M.). J.C. is a Leukemia & Lymphoma Society Scholar. M.M. is a Howard Hughes Medical Institute Faculty Scholar. R. Su and J.C. conceived and designed the project, and supervised the research; R. Su, Y.L. M.G. L.H. M.W. X.D. H.L. Y.H. L.G. C.L. Z.Z. S.R. B.T. Y.Q. X.Q. E.P. J.X. H.Q. W.L. C.S. H.W. H.H. Z.C. X.W. D.H. and J.C. performed experiments and/or data analyses; L.D. performed the bioinformatics analysis; R. Su, M.W. J.S. P.K. B.Z. M.J.O. M.M. G.M. R. Salgia, L.L. A.T.F. Z.L. J.C.M. M.M. D.H. and J.C. contributed reagents/analytic tools and/or grant support; R. Su and J.C. wrote the paper. All authors discussed the results and commented on the manuscript. A provisional patent was filed, with J.C. R. Su, D.H. X.D. H.L. and J.X. as inventors. J.C. is the scientific founder of Genovel Biotech Corp. and holds equities with the company. A.T.F. has done consultancy work for Celgene, Agios, Astellas, Daiichi Sankyo, and Abbvie, and Celgene and Agios are providing funding for two ongoing clinical trials that A.T.F. is running as investigator-initiated studies. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = jul,
day = "13",
doi = "10.1016/j.ccell.2020.04.017",
language = "English (US)",
volume = "38",
pages = "79--96.e11",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",
}